US Supreme Court Declines Review Of False Claims Act, PCSK9, Hep C Patents
Executive Summary
Gilead disputed Campie FCA decision, Amgen challenged Repatha ruling, and Merck challenged "unclean hands" defense against damages. Patent and Trademark Office wants court to determine if its attorneys' fees should be covered by patent applicants challenging its decisions.
You may also be interested in...
Can Government Petition PTAB To Review Patents? Supreme Court Seems Skeptical
Justice Sotoymayor suggests 'the deck is stacked' against private citizen who is dragged by government into AIA's post-grant review proceedings. Court denies petition seeking to revive Maryland's anti-price gouging law.
Federal Circuit Tosses Diagnostic Patent, Spurring Biopharma Calls For Congressional Action
A divided panel finds Athena Diagnostics' patent on method to diagnose myasthenia gravis is invalid; in dissent, Judge Newman cites industry concerns that the decision will deter development of new diagnostic methods.
Product Liability Defense Favored By Industry Appears To Have Supreme Court Support
US FDA's rejection of Merck's proposed Fosamax label warning preempts state-law tort suits, several Justices appear to conclude, as Kagan and Sotomayor question whether the proposal focused on the right risk.